we got a taste of your technical analysis drivel .... now we...

First 34 Last

Share
Profile

Follow
Hiro

135 Posts.

29

01/03/19

10:27

Post #: 37616727
Share

Originally posted by dkayed: ↑

Never read through such a hilarious half yearly. What an abysmal result

$11k revenue - not even enough to cover 1/10th of Director fees. Hilarious. How can they justify paying themselves $120k for HALF a year??

Having to cite Placement fees in your explanation on the opening page to masquerade your loss - surely that's taking the piss?

Management maybe should put some of that $11k revenue to better quality reporting - not sure how they expect anyone to be able to read that table on page 7 - LOL.

Then to top it off the section about commercialisation looks akin to a uni student copy pasting what commercialisation is from the internet. Absolute gold.

What a farce. This will end in so many tears. My initial PT of $3 will come a lot sooner than expected now. Then only continue down from there. Holders getting reassured by price being artificially pushed up by orders of $3k?? Must feel good. If anyone with a serious holding wanted to exit they'd push it down about 50c+ in half a day.

Bring out the pitchforks and watch the mob pounce on me now! Never seen such a toxic forum but amongst all the berating uprampers all of the above needs to be said! Hopefully can save new investors a buck or two

GLTAH

Expand

we got a taste of your technical analysis drivel .... now we know how conduct your FA .

So please enlighten us obee'dumb ... can a company's market cap increase despite it having ZERO revenue ? Can a company's market cap increase despite it NOT making a profit ?

PO3 Price at posting: $3.51 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

TI1

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ZNO

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

HAW

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The iron ore comeback: Can it last?

There are more pages in this discussion • 123 more messages in this thread...

First 34 Last

Add PO3 (ASX) to my watchlist

(20min delay)
Last 22.0¢		Change 0.000(0.00%)		Mkt cap ! $7.078M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

we got a taste of your technical analysis drivel .... now we...

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Hastings progressing Yangibana to production with lower costs

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The iron ore comeback: Can it last?

Featured News

Featured News

we got a taste of your technical analysis drivel .... now we...

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Hastings progressing Yangibana to production with lower costs

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The iron ore comeback: Can it last?

Featured News

Featured News